neuropsychiatric disease | GenomeWeb

neuropsychiatric disease

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

NEW YORK (GenomeWeb) – Assurex Health today said that the US Department of Veterans Affairs has approved the firm's GeneSight Psychotropic test for use in VA facilities nationwide.

NEW YORK (GenomeWeb News) – Emory University said on Tuesday that it will lead an effort to sequence the genomes of 1,000 people who suffer from 22q11.2 deletion syndrome as part of an international consortium that has received $12 million from the National Institute of Mental Health to study how

NEW YORK (GenomeWeb News) – The National Institute of Mental Health will award around $3 million to fund as many as six projects that pursue research into a genetic microdeletion that has been associated with a range of neuropsychiatric disorders.

NEW YORK (GenomeWeb News) – Pharmacogenomics firm AssureRx Health announced on Wednesday it has closed its Series C financing, raising $12.5 million.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A public-private consortium to generate and analyze large-scale genomic data from patients with neuropsychiatric diseases has launched.

The Welsh government has awarded over $9 million for a new mental health research center, cancer genetics studies, and a new imaging unit.

The firm's GeneSightRx technology uses DNA from a cheek swab to measure and analyze genetic variants to determine how a patient will respond to psychotropic medications.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.